The role of IL32 in the immunemodulation of mesenchymal stem cell and the stromal-hematopoietic interection in myelodysplastic syndrome

• Grant number: 12/13068-0
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: November 01, 2012
• End date: June 30, 2016
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Patricia Maria Bergamo Favaro
• Grantee: Matheus Rodrigues Lopes
• Host Institution: Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

In addition to its support role during hematopoiesis, either by secretion of soluble factors or cell-cell interactions, recently, mesenchymal stem cells (MSCs) have become candidates for cell therapy, mainly because of its immunomodulatory capacity. Myelodysplastic syndromes (MDS) are hematologic malignancies that result from changes in hematopoietic stem cell characterized by ineffective hematopoiesis and peripheral cytopenia. The cause and progression of MDS are not known, but it is clear that involves a complex cellular process. MSCs of MDS patients have been described with immunomodulatory and immunophenotypic changes, and recently has been described increased expression of interleukin 32 (IL32) in these cells. Thus, it is important to characterize the functional relevance of the increased expression of IL32, as previously described as a hematopoietic growth factor, and overexpressed in many inflammatory diseases, infectious, viral, autoimmune diseases and some types of cancer and also with antitumor properties. Therefore the aims of this study are to analyze the expression of IL32 MSCs in patients with MDS and correlate its expression with immunomodulatory capacity, with the immunophenotypic characteristics of these cells and subsets of the disease. Moreover, to characterize the role of this cytokine in the proliferation, migration and their ability in protecting apoptosis and sensitivity to chemotherapy in HS-5 cell line inhibited for the IL32 expression. We also intend to establish a model xenoimplante AML cells to address the IL32 antitumor role.

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

LOPES, Matheus Rodrigues. Characterization of bone marrow mesenchymal stromal cells derived from myelodysplastic syndromes and acute myeloid leukemia patients and biology study of interleukin-32 in the medular microenvironment. 2016. Doctoral Thesis - Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas Campinas, SP.